Hologic, Inc.

Hologic, Inc. is an American medical technology company dedicated to improving women's health and well-being through early detection and treatment of diseases. Headquartered in Marlborough, Massachusetts, the company develops, manufactures, and supplies a comprehensive portfolio of diagnostic products, medical imaging systems, and surgical solutions globally.

The company operates across four primary segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Its key offerings include molecular diagnostic instrumentation such as the Panther and Panther Fusion systems, digital diagnostics systems like the ThinPrep Pap test and Genius Digital Diagnostics System, and various products for breast biopsy, endometrial ablation, and bone densitometry. Hologic's products are distributed to clinical laboratories, hospitals, healthcare providers, and surgeons worldwide.

In April 2026, Hologic transitioned to a private company following its acquisition by funds managed by Blackstone and TPG, with its common stock ceasing trading on Nasdaq. José (Joe) E. Almeida was appointed Chief Executive Officer, succeeding Stephen P. MacMillan upon the acquisition's completion. Recent developments include an expanded CE-IVDR mark for its Aptima HPV Assay for self-collected samples in July 2026 and a significant patent victory against Siemens Healthineers concerning breast cancer detection technology in June 2026.